OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC

October 29th 2020

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Dr. Wolin on the Treatment Landscape of NETs

October 29th 2020

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Dr. Goff on the Need to Identify Novel Targets in HCC

October 29th 2020

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer

October 29th 2020

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Dr. Azad on Third-Line Treatment Options in CRC

October 29th 2020

Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC

October 28th 2020

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.

Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC

October 28th 2020

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Dr. Luke on the Importance of BRAF in Melanoma

October 28th 2020

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma

October 28th 2020

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC

October 28th 2020

Benjamin P. Levy, MD, discusses the mechanism of action of telaglenastat in non–small cell lung cancer.

Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer

October 28th 2020

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

Dr. Gradishar on the Expanding Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 28th 2020

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Bahary on the Prognosis of BRAF-Mutant Colorectal Cancer

October 28th 2020

Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.

Dr. Kasi on the Role of MRD Testing in CRC

October 28th 2020

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Dr. Theurillat on Castration and AR Inhibition in Prostate Cancer

October 27th 2020

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Dr. Davids on the Future of CAR T-Cell Therapy in CLL

October 27th 2020

Matthew S. Davids, MD, MMSc, discusses the future of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Lin on the Role of Genomic Markers in Prostate Cancer

October 27th 2020

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Dr. Abdulkadir on the Rationale to Target MYC in Prostate Cancer

October 27th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.

Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal Sarcoma

October 27th 2020

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Dr. Tap on the Evolution of Precision Medicine in Soft Tissue Sarcomas

October 27th 2020

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.